Over the past five years, the cosmetic industry has met with several legislative changes. Within the new legislative package, including the new REACH and CLP, it is important to find a comfortable routine that will minimize costs while staying effective and compliant with all regulations.
Interview with Michael Seres
Read the interview with our speaker Michael Seres, Patient Representative from the United Kingdom.
You run many activities in the area of patient empowerment. Which of them do you devote most of your time to, and why? My big passion is the role that patients play in healthcare – how we can become more engaged and a part of every decision made about our care. I very much believe that technology can help with this. We all use digital and social media in all aspects of our lives except healthcare, so I am especially keen to show how tools such as SMS, social media and Skype can become part of the healthcare interaction between patient and doctor.
I also founded a connected device company while going through a transplant. That saw me engaging with healthcare from a different perspective. This now takes up a large part of my time as we learn how to scale up a patient-led innovation.
As a "Voice of the Patients”, what would you say is the biggest issue that needs to be solved?Firstly, I would say that I do not represent anyone. I just try and use my own experiences to show others that there are new ways of engaging; new tools at our disposal to build relationships. The biggest issue is fear. At the moment, it takes great bravery from clinicians to engage with patients in a different way. It also takes great bravery for pharma companies to come out from behind the curtain and talk to us. For me, the biggest challenge is cultural change. Going from a default position of "no, we can’t" to a position of "yes, and how do we figure out how to do it?"
Can you provide us with deeper insight into your activities as a patient ambassador?I have a number of roles within healthcare and feel very lucky to be part of many conversations. The role of patient entrepreneur is something I take very seriously. I want my company 11Health to show other patients that they can provide solutions to issues and they can then scale them up.I am Co-Chair of the NHS User Council on Digital Health, which is an exciting way to be part of the future of technology within the NHS. We play a strategic role in ensuring that all new technology is steeped in patient feedback, co-development and co-design. Finally, I am the first e-Patient-in-Residence at Stanford for their MedicineX programme. My role is to deliver insight on how patients can play a key role in education, design and innovation in healthcare.None of what I’ve done has ever been planned. I have just been lucky enough to use my personal experiences to play a very small role in the development of healthcare and especially digital health.
Interested in this topic?
Advanced Protein Aggregation & Characterization
This training will focus on occurrence of particles in drug products, effects of protein aggregates, critical process and parameters. Attendees will gain overview of on utility and limits of predictive experiments, learn concerns from the authorities and relevant aggregation guidelines, and more.
CMC Analytical Comparability: Methods & Strategies for Biologics, Biosimilars & Biobetters
Attendees will be introduced to comparability in biosimilar development, the analytical strategies of protein characterization of biosimilars, the structure of proteins, in vitro pharmacology and much more.
Corporate Compliance & Transparency in the Pharmaceutical Industry
This two-day conference will serve as a platform for an open and dynamic dialogue with HCPs and patients to achieve common goals. Learn how to embed compliance in the business and develop one simple system for managing compliance & transparency in a complex and regulated environment.
Driving the national agenda of Medical tourism through PX Excellence
Read the interview with Dr. Layla Al-Marzouqi, Director of Medical Tourism Council at Dubai Health Authority, and learn how to enrich patient experience and quality of healthcare.
No more trouble with dangerous good shipments
Global temperature controlled pharmaceutical shipments are constantly faced with new logistics challenges and regulations. This January 2017, IATA Dangerous Goods Regulations added further complexity to shipping cold chain products compliantly.
5 Changes in Signal Detection Management
The European Medicines Agency, regulatory authorities in the Member States and marketing authorisation holders are responsible for detecting and managing safety signals. A safety signal is generally defined as information about a new or known Adverse Event that may have been caused by a medicine, where it is therefore necessary to conduct further investigation. Evaluation of safety signals plays a major role within pharmacovigilance. Therefore, it is vital for regulatory authorities to know the latest updates detailing the risks and benefits of medicines. The EudraVigilance database is an important source of information on suspected adverse reactions and signals.